Reply to: Statistical and Methodological Considerations in the Evaluation of Ultra-Low-Dose Nivolumab

Kumar Prabhash¹, Vanita Noronha¹, Akash Pawar¹+2

• ¹Kumar Prabhash, MD, DM, MBBS, Department of Medical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai, India, Department of Medical Oncology, Homi Bhabha Cancer Hospital and Research Centre, Muzaffarpur, India; Vanita Noronha, MD, DM, MBBS, Department of Medical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai, India; Akash Pawar, MSc, Department of Statistics, Advanced Centre for Treatment, Research and Education in Cancer, Homi Bhabha National Institute (HBNI), Mumbai, India, Ankush Shetake, MSc, Department of Statistics, Homi Bhabha Cancer Hospital and Research Centre, Muzaffarpur, India; and Rajendra Badwe, MS, Department of Surgical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai, India.